So if the molecular analysis Co's that analyse the patients dead22 Sep 2023 16:18
Circulating cancer cells (e.g Breast cancer ones in the blood stream) conclude that having live ones to analyse at the same time (using Angle's Parsortix machine) would give a better picture of the patients cancer then we are on a winner. I have concluded we are on a winner. It seems pretty obvious to me that to get the complete picture of the state of a persons matasticised cancer you need to analyse the dead cancer cells (e.g dead breast cancer cells in the blood) and the ones that are still alive. Clearly if the person is having treatment to kill the cancer cells the live ones will obviousy give more information, the most obvious one being why is it still alive? Plus much more info.
It's a stonking buy IMHO.
I think the market is undervaluing Angle by a massive amount, and it will get a bid.
All IMHO.